Everest Medicines, a biopharmaceutical company dedicated to developing, manufacturing, and commercializing innovative medicines and vaccines, has announced that the Pharmaceutical Administration Bureau of the Macao Special Administrative Region, China, has accepted its New Drug Application (NDA) for Nefecon®.

SimBioSys, a pioneering TechBio company leveraging Artificial Intelligence (AI), spatial biophysics, and data science to redefine precision medicine and combat cancer, proudly announces its role as one of the founding members of the CancerX initiative.

AGC Biologics, a prominent global biopharmaceutical contract development and manufacturing organization (CDMO), has unveiled the expansion of its Longmont, Colorado facility with the addition of three state-of-the-art Grade B cell therapy manufacturing facilities.

Paradigm Therapeutics Inc., a biopharmaceutical company, has successfully finalized the acquisition of the global rights for SD-101, a topical whole-body treatment for all subtypes of Epidermolysis Bullosa (EB), from Amicus Therapeutics. The specifics of the agreement have not been publicly disclosed.

LEO Pharma has officially announced a strategic move to acquire Timber Pharmaceuticals, Inc., a company listed on the NYSE American under the ticker symbol TMBR.

Enveric Biosciences (NASDAQ: ENVB), a biotech firm dedicated to pioneering innovative neuroplastogenic small-molecule therapeutics aimed at addressing anxiety, depression, and addiction disorders, has recently achieved a significant milestone.

Everest Medicines (HKEX: 1952.HK) has announced that the U.S. Food and Drug Administration (FDA) has accepted the submission for the supplemental New Drug Application (sNDA) for Nefecon® from its partner Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) and has granted Priority Review.

Reykjavik-based pharmaceutical discovery company, 3Z, has partnered with causal AI firm biotx.ai, based in Germany and the US, with the aim of revolutionizing the development of drugs for ADHD. Through the integration of advanced AI modeling techniques, this collaboration seeks to bridge the gap between animal-based studies and human clinical trials, facilitating a more precise and efficient translation of promising therapies.

Response Pharmaceuticals, Inc. today announced the successful completion of its Phase 1B clinical trial for the company's lead drug candidate, RDX-002, a first-in-class inhibitor of intestinal

Neurophth Therapeutics, Inc. announced today that the first patient has been dosed in the international multi-region, multi-center Phase I/II clinical trial for the treatment of Leber hereditary